Applied Therapeutics, Inc. stock is down -27.6% since 30 days ago. The next earnings date is Mar 21, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 60% of the previous 4 November’s closed higher than October.
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosmia in healthy volunteers and adults. The company also develops AT-001 that is in phase III clinical trials for treating diabetic cardiomyopathy, as well as for treatment of diabetic peripheral neuropathy.